Journal: Oncology reports

Article Title: PTEN enhances G2/M arrest in etoposide-treated MCF‑7 cells through activation of the ATM pathway.

doi: 10.3892/or.2016.4674

Figure Lengend Snippet: Figure 6. PTEN promotes etoposide-induced inactivation of CDC25C. (A) The control and PTEN-knockdown MCF-7 cells were treated with different doses of etoposide (ETOP) for 8 h and phospho-CDC25C (inac- tive form) was detected by western blotting. Representative images of western blotting are presented for both control and PTEN-knockdown groups. (B) The relative expression level of phosphorylated CDC25C was quantified against total CDC25C that was first normalized by β-actin. Data are presented as means ± SE. *p<0.05 in comparison to the respective phospho‑CDC25C (S216) in the control group.

Article Snippet: Anti-phospho-ATM, anti-Chk2, anti-phosph-Chk2 (T68), anti-phospho-p53 (S15) and anti-phospho-CDC25C (S216) antibodies were purchased from Cell Signaling.

Techniques: Control, Knockdown, Western Blot, Expressing, Comparison

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway

doi: 10.1007/s00432-024-05747-w

Figure Lengend Snippet: KIF22 transcriptionally regulated the expression of CDC25C. A Results of an enrichment for regulation of mitotic cell cycle and cell cycle G2/M phase transition, as shown by performing GSEA. B Co-expression analysis performed by TCGA data between KIF22 and CDC25A, CDC25B, and CDC25C. C The mRNA expression of KIF22 was detected by the specimens from MM patients and healthy donors. D Co-expression analysis performed by data of MM patients samples between KIF22 and CDC25A, and CDC25B and CDC25C. E The mRNA expressions of CDC25A, CDC25B, and CDC25C were detected in MM cells after the knockdown or overexpression of KIF22. F PCR amplification of the anti‑KIF22 antibody‑enriched CDC24C promoter fragment in RPMI 8226 cells by ChIP assay. G Luciferase activity of pGL3‑CDC25C-Mut, pGL3‑CDC25C-WT plasmids in 293 T cells co‑transfected with siKIF22 or siNC examined by luciferase reporter assays. H The ERK/CDC25C/CDK1/cyclin B1 pathway was detected in MM cells after the knockdown or overexpression of KIF22. Mut mutation type. WT wild type. * P < 0.05, ** P < 0.01, *** P < 0.001. n.s no significance

Article Snippet: Primary antibodies included KIF22 (13403-1-AP, 1:200, proteintech), CDC25C (16485-1-AP, 1:500, proteintech), Ki-67(28074-1-AP, 1:500, proteintech), and CD38(25284-1-AP, 1:300, proteintech).

Techniques: Expressing, Sublimation, Knockdown, Over Expression, Amplification, Luciferase, Activity Assay, Mutagenesis

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway

doi: 10.1007/s00432-024-05747-w

Figure Lengend Snippet: CDC25C inhibitor suppressed proliferation and arrested cell cycle of MM cells. A Efficiency of CDC25C inhibitor NSC95397 on suppressing the expression of CDC25C. B The CDC25C/CDK1/cyclinB1 pathway was inhibited after using CDC25C inhibitor in MM cells. C CCK-8 assay was used to determine the appropriate concentration of NSC95397 on MM cells and its effect on MM cell proliferation. D CDC25C inhibitor arrested MM cells at the G2/M phase. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: Primary antibodies included KIF22 (13403-1-AP, 1:200, proteintech), CDC25C (16485-1-AP, 1:500, proteintech), Ki-67(28074-1-AP, 1:500, proteintech), and CD38(25284-1-AP, 1:300, proteintech).

Techniques: Expressing, CCK-8 Assay, Concentration Assay

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway

doi: 10.1007/s00432-024-05747-w

Figure Lengend Snippet: KIF22 regulates MM progression through the CDC25C/CDK1/cyclinB1 pathway. A The CDC25C/CDk1/cyclinB1 pathway was detected by Western blotting in the overexpression of KIF22 MM cells treated with NSC95397. B–C The CCK-8 and 5-ethynyl-20-deoxyuridine (EdU) incorporation assay results in the overexpression of KIF22 MM cells treated with NSC95397. D Cell cycle results in the overexpression of KIF22 MM cells treated with NSC95397. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: Primary antibodies included KIF22 (13403-1-AP, 1:200, proteintech), CDC25C (16485-1-AP, 1:500, proteintech), Ki-67(28074-1-AP, 1:500, proteintech), and CD38(25284-1-AP, 1:300, proteintech).

Techniques: Western Blot, Over Expression, CCK-8 Assay

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway

doi: 10.1007/s00432-024-05747-w

Figure Lengend Snippet: Knockdown of KIF22 suppressed the growth of subcutaneous tumor in nude mice. A-B Efficiency of KIF22 knockdown was detected in mRNA and protein level. C Representative images of tumors formed in the Lv-NC group and Lv-shKIF22 group. D Tumor volume and growth curves. E HE stain and immunohistochemistry revealed the expression of KIF22, CDC25C,Ki-67, and CD38 in the tumor tissues from mice. F Representative images of tumors formed in the NC group and OE-KIF22 group. G Tumor volume and growth curves. H HE stain and immunohistochemistry revealed the expression of KIF22, CDC25C, Ki-67, and CD38 in the tumor tissues of mice. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: Primary antibodies included KIF22 (13403-1-AP, 1:200, proteintech), CDC25C (16485-1-AP, 1:500, proteintech), Ki-67(28074-1-AP, 1:500, proteintech), and CD38(25284-1-AP, 1:300, proteintech).

Techniques: Knockdown, H&E Stain, Immunohistochemistry, Expressing

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: KIF22 promotes multiple myeloma progression by regulating the CDC25C/CDK1/cyclinB1 pathway

doi: 10.1007/s00432-024-05747-w

Figure Lengend Snippet: Mechanism diagram of KIF22 in regulating the progression of multiple myeloma (drawn by Figdraw). KIF22 positively transcriptionally regulated the expression of CDC25C by binding to its promoter and then regulated the CDC25C/CDk1/cyclinB1 pathway in MM cells

Article Snippet: Primary antibodies included KIF22 (13403-1-AP, 1:200, proteintech), CDC25C (16485-1-AP, 1:500, proteintech), Ki-67(28074-1-AP, 1:500, proteintech), and CD38(25284-1-AP, 1:300, proteintech).

Techniques: Expressing, Binding Assay

Journal: BioMed Research International

Article Title: Curcumin Inhibits Proliferation and Epithelial-Mesenchymal Transition in Lens Epithelial Cells through Multiple Pathways

doi: 10.1155/2020/6061894

Figure Lengend Snippet: Curcumin decreased mRNA transcription and protein expression of cell cycle-related proteins at 10 μ M. (a) The mRNA transcriptions of cell cycle-related proteins cyclin B1 and CDK1 in LECs treated with curcumin (0, 5, and 10 μ M) for 48 h were detected by real-time PCR. GAPDH was used as an internal control. ∗ P < 0.05, vs. the control. (b) Expressions of cell cycle-related proteins cyclin B1, CDK1, and CDC25C in curcumin-treated LECs were determined using western blot analysis. α -Tubulin was used as an internal control. (c) Densitometric analyses of the protein expression levels of cyclin B1, CDK1, and CDC25C from the western blots are shown. # P < 0.05, ## P < 0.01 vs. the control.

Article Snippet: Other antibodies used included CDK1, cyclin B1, CDC25C, E-cadherin, fibronectin, α -SMA (Boster, Wuhan, Hubei, China), Notch1, Notch2, Smad2/3, p-Smad2/3 (Santa Cruz, CA, USA), p38, p-P38, Akt, p-Akt, ERK1/2, and p-ERK1/2 (CST, MA, USA).

Techniques: Expressing, Real-time Polymerase Chain Reaction, Control, Western Blot